FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2415703012> ?p ?o ?g. }

• W2415703012 endingPage "94" @default.
• W2415703012 startingPage "189" @default.
• W2415703012 abstract "To evaluate the efficacy of the treatment with alglucerase (Ceredase) in spanish patients diagnosed of Gaucher disease type 1 (GD).A national inquiry has been performed among the hospitals with GD's patients on therapy. A form including pretherapy haemoglobin, platelet levels, liver and spleen size and bone lesions was submitted to the participating centers. A quarterly follow-up was requested. Descriptive statistics and frequency distribution analysis were performed through a Statview 4.02 database.Participating centers 22; evaluable patients 34. The mean age at diagnosis was 18.9 +/- 12.7 years, being the M/F ratio 0.47. Organomegaly was present in 88.2% and 70.5% had bone disease. Low haemoglobin levels (< 110 g/L) had detected in 48.6%, leucopenia (< 4.0 x 10(9)) were in 36.6% and low platelet level (< 15.0 x 10(9)) in 73.2%. The most frequent mutations observed were N370S (39.7% of the alleles detected), and L444P(20.4%). Time on therapy: between 6-12 months, 18 patients, > 1 year 16 patients, > 2 years 11 (5 reaching 3 years). Dosage schedulle:a) 10-20 U/Kg/week, 8 cases, b) 30-60 U/Kg/ two weeks, 26 cases. Eight patients were splenectomized before therapy. After one year on therapy haemoglobin and platelet levels become normal in 82.3% and 47.0% of patients respectively and the liver and spleen size were reduced 66 and 42%. There are not significant differences among weekly (8 patients) or forthnightly (26 patients) dosages except in the spleen size more reduced in the later group (43% vs 65%). Haemoglobin and platelet levels were similar among splenectomized or non-splenectomized patients, but the reduction of the liver size (80 vs 17%) was significatively greater in the former. One patient developed an asymptomatic antialglucerase antibody during the first month on therapy.The infusion of alglucerase is effective in the treatment of the GD type 1, with a significant reduction of organomegalies and a definite improvement in haemoglobin and platelet levels. The efficacy seems to be unrelated with the schedule employed or the splenic removal; nevertheless liver enlargement was more reduced in the splenectomized cases and the spleen size among the patients with the regimen of high dose/low frequence. Bone healing requires a very long time therapy. The treatment is safe and the antibody production low." @default.
• W2415703012 created "2016-06-24" @default.
• W2415703012 creator A5026272581 @default.
• W2415703012 creator A5050458862 @default.
• W2415703012 creator A5073093146 @default.
• W2415703012 date "1997-06-01" @default.
• W2415703012 modified "2023-09-23" @default.
• W2415703012 title "[Alglucerase treatment of type I Gaucher's disease. Preliminary results in Spain. Spanish Group on Gaucher's Disease]." @default.
• W2415703012 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9381260" @default.
• W2415703012 hasPublicationYear "1997" @default.
• W2415703012 type Work @default.
• W2415703012 sameAs 2415703012 @default.
• W2415703012 citedByCount "2" @default.
• W2415703012 crossrefType "journal-article" @default.
• W2415703012 hasAuthorship W2415703012A5026272581 @default.
• W2415703012 hasAuthorship W2415703012A5050458862 @default.
• W2415703012 hasAuthorship W2415703012A5073093146 @default.
• W2415703012 hasConcept C126322002 @default.
• W2415703012 hasConcept C141071460 @default.
• W2415703012 hasConcept C162156334 @default.
• W2415703012 hasConcept C187212893 @default.
• W2415703012 hasConcept C2776723260 @default.
• W2415703012 hasConcept C2778551932 @default.
• W2415703012 hasConcept C2779134260 @default.
• W2415703012 hasConcept C2779969927 @default.
• W2415703012 hasConcept C2780931953 @default.
• W2415703012 hasConcept C71924100 @default.
• W2415703012 hasConcept C89560881 @default.
• W2415703012 hasConcept C90924648 @default.
• W2415703012 hasConceptScore W2415703012C126322002 @default.
• W2415703012 hasConceptScore W2415703012C141071460 @default.
• W2415703012 hasConceptScore W2415703012C162156334 @default.
• W2415703012 hasConceptScore W2415703012C187212893 @default.
• W2415703012 hasConceptScore W2415703012C2776723260 @default.
• W2415703012 hasConceptScore W2415703012C2778551932 @default.
• W2415703012 hasConceptScore W2415703012C2779134260 @default.
• W2415703012 hasConceptScore W2415703012C2779969927 @default.
• W2415703012 hasConceptScore W2415703012C2780931953 @default.
• W2415703012 hasConceptScore W2415703012C71924100 @default.
• W2415703012 hasConceptScore W2415703012C89560881 @default.
• W2415703012 hasConceptScore W2415703012C90924648 @default.
• W2415703012 hasIssue "3" @default.
• W2415703012 hasLocation W24157030121 @default.
• W2415703012 hasOpenAccess W2415703012 @default.
• W2415703012 hasPrimaryLocation W24157030121 @default.
• W2415703012 hasRelatedWork W1972456314 @default.
• W2415703012 hasRelatedWork W1984605857 @default.
• W2415703012 hasRelatedWork W1988253866 @default.
• W2415703012 hasRelatedWork W2005519754 @default.
• W2415703012 hasRelatedWork W2411277415 @default.
• W2415703012 hasRelatedWork W2415703012 @default.
• W2415703012 hasRelatedWork W2419618477 @default.
• W2415703012 hasRelatedWork W2424446336 @default.
• W2415703012 hasRelatedWork W2567269117 @default.
• W2415703012 hasRelatedWork W2600546709 @default.
• W2415703012 hasVolume "42" @default.
• W2415703012 isParatext "false" @default.
• W2415703012 isRetracted "false" @default.
• W2415703012 magId "2415703012" @default.
• W2415703012 workType "article" @default.